6533b7d4fe1ef96bd1261da6

RESEARCH PRODUCT

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan

Maria Jose FabiaJosep Redon

subject

Medicine (General)Angiotensin receptorReceptors AngiotensinAngiotensin Receptor Antagonistsbusiness.industryImidazolesTetrazolesBlood PressurePharmacologyAngiotensin IIBlockadeAngiotensin Receptor AntagonistsR5-920Treatment OutcomeEndocrinologyBlood pressurePharmacotherapyRenin–angiotensin systemInternal MedicineHumansMedicineDrug Therapy CombinationbusinessOlmesartanmedicine.drug

description

A range of angiotensin II receptor blockers (ARB) is available, and analyses suggest there are differences between agents in terms of antihypertensive efficacy and 24-hour blood pressure control.This review assesses the data comparing olmesartan with other ARBs in terms of blood pressure reductions, goal achievement, 24-hour control and speed of onset. Olmesartan seems to have a more favourable efficacy profile relative to standard doses of the ARBs used in comparative studies; results consistent with the high degree of blockade of the angiotensin II type 1 receptor for olmesartan.Taken together, there might be differences between ARBs regarding their blood pressure lowering efficacy, and these results may provide further support of the benefits of olmesartan therapy since choice of an effective agent is crucial in antihypertensive therapy.

yearjournalcountryeditionlanguage
2009-08-03Journal of the Renin-Angiotensin-Aldosterone System
https://doi.org/10.1177/1470320309342735